Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GluA2-containing AMPA receptors are a major class of ionotropic glutamate receptors that mediate fast excitatory neurotransmission throughout the central nervous system (UniProt P42262). The inclusion of the GluA2 (formerly GluR2) subunit is a critical regulatory feature, as post-transcriptional RNA editing at the Q/R site renders these receptors impermeable to calcium ions, thereby protecting neurons from excitotoxic damage (Wright & Vissel, 2012). These receptors play a fundamental role in synaptic plasticity, including long-term potentiation (LTP) and long-term depression (LTD), which are the cellular correlates of learning and memory (StatPearls, 2023). Dysregulation of GluA2, such as reduced expression or defective RNA editing, is strongly associated with the pathogenesis of amyotrophic lateral sclerosis (ALS), where increased calcium influx leads to motor neuron death (Kwak & Kawahara, 2005). In clinical practice, drugs like perampanel act as non-competitive antagonists of these receptors to manage partial-onset seizures by dampening excessive excitatory signaling (French et al., 2012). Consequently, GluA2-containing AMPA receptors represent a pivotal therapeutic target for a wide range of neurological and psychiatric disorders characterized by glutamatergic imbalance.
Non-competitive antagonism, competitive antagonism, or allosteric modulation of the ion channel to regulate sodium and potassium conductance while maintaining calcium impermeability.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamate ionotropic receptor AMPA type subunit 2-containing receptor (GluA2-containing AMPAR).